Esperion Therapeutics Inc (NASDAQ:ESPR) shares, rose in value on Wednesday, June 18, with the stock price up by 0.92% to the previous day’s close as strong demand from buyers drove the stock to $1.10.
Actively observing the price movement in the last trading, the stock closed the session at $1.09, falling within a range of $1.065 and $1.13. The value of beta (5-year monthly) was 0.654. Referring to stock’s 52-week performance, its high was $3.94, and the low was $0.69. On the whole, ESPR has fluctuated by 27.33% over the past month.
With the market capitalization of Esperion Therapeutics Inc currently standing at about $218.02 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-06.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ESPR’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ESPR currently trading nearly 6.54% and 13.71% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.45, while the 7-day volatility ratio is showing 3.58% which for the 30-day chart, stands at 5.05%. Furthermore, Esperion Therapeutics Inc (ESPR)’s beta value is 0.65, and its average true range (ATR) is 0.08.
A comparison of Esperion Therapeutics Inc (ESPR) with its peers suggests the former has fared considerably weaker in the market. ESPR showed an intraday change of 0.92% in last session, and over the past year, it shrunk by -63.21%%.
Data on historical trading for Esperion Therapeutics Inc (NASDAQ:ESPR) indicates that the trading volumes over the past 10 days have averaged 3.3 and over the past 3 months, they’ve averaged 5.25 million. According to company’s latest data on outstanding shares, there are 196.66 million shares outstanding.
Nearly 1.83% of Esperion Therapeutics Inc’s shares belong to company insiders and institutional investors own 57.31% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 26.34 million shares as on 2025-05-30, resulting in a short ratio of 4.35. According to the data, the short interest in Esperion Therapeutics Inc (ESPR) stood at 1335.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 29.86 million. The stock has fallen by -50.00% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ESPR stock heading into the next quarter.
